« Dr. StrangePost - Or How I Learned to Love the Blog.................... | Main | Seattle Genetics Parlays ADC into CASH »



TrackBack URL for this entry:

Listed below are links to weblogs that reference Amylin Counting on Swift Bydureon Approval:


Feed You can follow this conversation by subscribing to the comment feed for this post.


More from Fierce Biotech on recent disappointing Bydureon results when compared to generic metformin. Amylin stock price drops.


The forbes blog reported today (June 15th) that Amylin announced results from a clinical trial where it beat most of its fancy biotech competitor drugs but failed to best a cheap generic called metformin.

Bruce Lehr

Pharmaceutical Business Review provides a further report on Roche's taspoglutide hitting on all cylinders in latest trial report.

Bruce Lehr

As mentioned at the tail end of the post, Roche is marching relentlessly closer to approval with its taspoglutide. Here is the latest from Fierce Biotech on Roche progress.

Bruce Lehr

Novo Nordisk reported results comparing its once-daily Victoza (its GLP-1 analog)versus Merck's DPP-4 inhibitor Januvia,http://bit.ly/cyImBV

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC

visited 6 states (46.1%)
Create your own visited map of Canada